Studies indicate that receptor status may undergo changes after neoadjuvant treatment, showcasing inconsistencies of approximately 3–5% in hormone receptor (HR) status and 10% in HER-2 status in breast cancers treated with current neoadjuvant regimens [19]. The gene discussed is ERBB2; the disease is breast carcinoma.